Literature DB >> 29205637

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.

Anna-Lena Volckmar1, Holger Sültmann2, Anja Riediger2, Thoas Fioretos3,4, Peter Schirmacher1, Volker Endris1, Albrecht Stenzinger1,5, Steffen Dietz2.   

Abstract

Recently, many genome-wide profiling studies provided insights into the molecular make-up of major cancer types. The deeper understanding of these genetic alterations and their functional consequences led to the discovery of novel therapeutic opportunities improving clinical management of cancer patients. While tissue-based molecular patient stratification is the gold standard for precision medicine, it has certain limitations: Tissue biopsies are invasive sampling procedures carrying the risk of complications and may not represent the entire tumor due to underlying genetic heterogeneity. In this context, complementary characterization of genetic information in the blood of cancer patients can serve as minimal-invasive 'liquid biopsy'. Fragments of circulating cell-free DNA (cfDNA) are released from tissues of healthy individuals as well as cancer patients. The fraction of cfDNA that is released from primary tumors or metastases (i.e. circulating tumor DNA, ctDNA) represents genetic aberrations in cancer cells, which are a potential source for diagnostic, prognostic, and predictive biomarkers. Recent studies have demonstrated technical feasibility and clinical applications including detection of drug targets and resistance mutations as well as longitudinal monitoring of tumors under therapy. To this end, a variety of pre-analytical procedures for blood processing, isolation and quantification of cfDNA are being employed and several analytical methods and technologies ranging from PCR-based single locus assays to genome-wide approaches are available, which considerably differ in sensitivity, specificity, and throughput. However, broad implementation of ctDNA analysis in daily clinical practice requires a thorough understanding of theoretical, technical, and biological concepts and necessitates standardization and validation of pre-analytical and analytical procedures across different technologies. Here, we review the pertinent literature and discuss the advantages and limitations of available methodologies and their potential applications in molecular diagnostics.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29205637     DOI: 10.1002/gcc.22517

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  60 in total

Review 1.  Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Authors:  Michael Allgäuer; Jan Budczies; Petros Christopoulos; Volker Endris; Amelie Lier; Eugen Rempel; Anna-Lena Volckmar; Martina Kirchner; Moritz von Winterfeld; Jonas Leichsenring; Olaf Neumann; Stefan Fröhling; Roland Penzel; Michael Thomas; Peter Schirmacher; Albrecht Stenzinger
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Does Size Matter? Comparison of Extraction Yields for Different-Sized DNA Fragments by Seven Different Routine and Four New Circulating Cell-Free Extraction Methods.

Authors:  Linda Cook; Kimberly Starr; Jerry Boonyaratanakornkit; Randall Hayden; Soya S Sam; Angela M Caliendo
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

Review 3.  Role of liquid biopsy in oncogene-addicted non-small cell lung cancer.

Authors:  Matteo Canale; Luigi Pasini; Giuseppe Bronte; Angelo Delmonte; Paola Cravero; Lucio Crinò; Paola Ulivi
Journal:  Transl Lung Cancer Res       Date:  2019-11

4.  The Ratio of ssDNA to dsDNA in Circulating Cell-Free DNA Extract is a Stable Indicator for Diagnosis of Gastric Cancer.

Authors:  Xuewen Huang; Qi Zhao; Xianyuan An; Jie Pan; Lanjing Zhao; Lanfeng Shen; Yiqiu Xu; Dandan Yuan
Journal:  Pathol Oncol Res       Date:  2020-07-06       Impact factor: 3.201

Review 5.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.

Authors:  E Alejandro Sweet-Cordero; Jaclyn A Biegel
Journal:  Science       Date:  2019-03-15       Impact factor: 47.728

Review 6.  Circulating tumor DNA in colorectal cancer: opportunities and challenges.

Authors:  Feifei Bi; Qiwei Wang; Qian Dong; Yuanhe Wang; Liqun Zhang; Jingdong Zhang
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

Review 7.  Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.

Authors:  Kristina Magaard Koldby; Michael Bau Mortensen; Sönke Detlefsen; Per Pfeiffer; Mads Thomassen; Torben A Kruse
Journal:  J Gastroenterol       Date:  2018-09-21       Impact factor: 7.527

8.  Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients.

Authors:  Shu Xia; Junyi Ye; Yu Chen; Analyn Lizaso; Le Huang; Lei Shi; Jing Su; Han Han-Zhang; Shannon Chuai; Lingling Li; Yuan Chen
Journal:  Transl Lung Cancer Res       Date:  2019-12

9.  Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer.

Authors:  Yuejiao Zhong; Qingyu Fan; Zhaofei Zhou; Yajing Wang; Kang He; Jianwei Lu
Journal:  Cancer Manag Res       Date:  2020-05-05       Impact factor: 3.989

Review 10.  Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.

Authors:  Alessia Cimadamore; Liang Cheng; Francesco Massari; Matteo Santoni; Laura Pepi; Carmine Franzese; Marina Scarpelli; Antonio Lopez-Beltran; Andrea Benedetto Galosi; Rodolfo Montironi
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.